Skip to main content

Table 3 Diagnosed migraine patients with a migraine specific prescription order 12-months before their completed survey

From: Combining patient reported outcomes and EHR data to understand population level treatment needs: correcting for selection bias in the migraine signature study

Specific treatment

All primary care patients diagnosed with migraine

% (SE) (N = 74,506)

Survey population with EHR diagnosed migraine

Survey population with diagnosed migraine corrected estimates

Respondents* % (SE) (n = 1320)

Non-respondents* % (SE) (n = 8815)

Corrected for sampling weight** % (SE) (n = 1320)

Corrected for sampling weight and response bias**,††† % (SE) (n = 1320)

Acute medication orders

All acute prescription treatments

26.4% (0.2%)

33.3% (1.3%)

20.4% (0.4%)

37.2%†† (0.5%)

26.2% (0.2%)

Non-narcotic analgesics

 1–2 orders

1.5% (0.1%)

2.1% (0.4%)

1.4% (0.1%)

1.6% (0.1%)

1.6% (0.1%)

 3 + orders

0.8% (0.09%)

1.0% (0.3%)

0.7% (0.09%)

1.0% (0.1%)

0.8% (0.03%)

Narcotic analgesics

 1–2 orders

1.8% (0.1%)

3.2% (0.5%)

1.6% (0.1%)

3.2%†† (0.2%)

2.0%††† (0.05%)

 3 + orders

1.8% (0.1%)

2.6% (0.4%)

1.7% (0.1%)

2.6%†† (0.2%)

1.8% (0.05%)

Triptans

 1–2 orders

14.2% (0.3%)

20.8% (1.1%)

13.0% (0.4%)

24.1%†† (0.4%)

14.3% (0.1%)

 3 + orders

4.1% (0.2%)

6.6% (0.7%)

3.7% (0.2%)

7.5%†† (0.3%)

4.1% (0.08%)

Other migraine-specific prescriptions

 1–2 orders

1.2% (0.1%)

2.6% (0.4%)

1.0% (0.1%)

2.5%†† (0.2%)

1.1% (0.04%)

 3 + orders

0.2% (0.04%)

0.4% (0.2%)

0.2% (0.04%)

0.4%†† (0.06%)

0.2% (0.01%)

Preventive medication orders

All preventive treatments

12.0% (0.1%)

17.1% (1.0%)

11.2% (0.3%)

16.8%†† (0.4%)

11.6% (0.1%)

Beta blockers, any

 1–2 orders

2.3% (0.2%)

3.1% (0.5%)

2.1% (0.1%)

3.2% (0.2%)

2.4% (0.06%)

 3 + orders

0.5% (0.07%)

0.9% (0.3%)

0.5% (0.08%)

0.9%†† (0.09%)

0.5% (0.02%)

Calcium channel blockers, any

 1–2 orders

0.9% (0.09%)

1.6% (0.3%)

0.8% (0.09%)

1.4%†† (0.1%)

0.9% (0.03%)

 3 + orders

0.2% (0.04%)

0.3% (0.1%)

0.2% (0.04%)

0.3% (0.06%)

0.2% (0.02%)

Antidepressants, any

 1–2 orders

3.1% (0.2%)

4.5% (0.6%)

3.0% (0.2%)

4.9%†† (0.2%)

3.1% (0.06%)

 3 + orders

1.0% (0.1%)

1.6% (0.3%)

0.9% (0.1%)

1.5%†† (0.1%)

0.9% (0.03%)

Anticonvulsants, any

 1–2 orders

3.9% (0.2%)

5.7% (0.6%)

3.6% (0.2%)

5.1%†† (0.2%)

3.8% (0.07%)

3 + orders

1.6% (0.1%)

2.3% (0.4%)

1.5% (0.1%)

2.1%†† (0.1%)

1.5% (0.04%)

OnabotulinumtoxinA, any

 1–2 orders

1.0% (0.1%)

1.8% (0.4%)

0.9% (0.1%)

1.6%†† (0.1%)

0.9% (0.03%)

3 + orders

0.06% (0.02%)

0.08% (0.08%)

0.06% (0.03%)

0.06% (0.02%)

0.05% (0.01%)

  1. The bold is used to distinguish the total for acute and preventive treatment proportions from the proportions for specific classes of acute and preventive medications
  2. Covariates in the response/non-response model include: age, sex, race/ethnicity, marital status, comorbidities, acute medication orders (0, 1–2 orders, 3 + orders), preventive medication orders (0, 1–2 orders, 3 + orders)
  3. *Not adjusted for strata distribution
  4. **In addition, adjusted for strata distribution
  5. Statistically significant comparing respondents versus population
  6. ††Statistically significant comparing adjusted for sample weight estimate versus source population
  7. †††None of variables is statistically significant comparing full adjustment estimate versus source population